COMMERCIALIZATION EXPERT JOINS THE CYTOPHAGE TEAM

Winnipeg, Manitoba - TheNewswire - July 6, 2023 - Cytophage Technologies Inc., a Canadian biotech company that produces bacteriophages, is pleased to announce the appointment of Mr. Andy Hurley as Director to the Cytophage Technologies Inc. Board of Directors as of June 30, 2023.  Mr. Hurley is an executive leader with over 30 years experience in pharmaceutical company operations and commercialization. He has launched more that 20 different drugs across global markets by building and leading successful teams.  Recently, Mr. Hurley joined Shield Therapeutics’ Executive Team as Chief Commercial Officer-United States. Before joining Shield, Mr. Hurley held senior leadership roles across commercialization, marketing, sales, and operations functions at companies including Syneos Health, Ocular Therapeutix, Sunovion, Dyax, NitroMed and Forest Pharmaceuticals. Mr. Hurley has a Bachelor of Science in Consumer Studies from the University of Vermont and did post-graduate work in Finance and Marketing at Bentley University's McCallum Graduate School of Business.

“We are excited to welcome Andy to the Cytophage board of directors and look forward to him sharing his wealth of knowledge based on his impressive history of successfully commercializing products,” said Harold Wolkin, chairman of the Cytophage Board of Directors.  “It’s this kind of expertise that will propel us to success as we launch our phage products in 2023.”

Also joining the team as an Advisor to the Board is Dr. Darwyn Kobasa. Dr. Kobasa will provide Cytophage with invaluable expertise in scientific research.  He is currently the Head, High Containment Respiratory Viruses at the National Microbiology Laboratory of the Public Health Agency of Canada.  Dr. Kobasa’s expertise is in the areas of molecular virology, pathogenesis, animal models of infection, and the development and evaluation of antiviral therapeutics and vaccines.  

Cytophage CEO, Dr. Steven Theriault, notes that “Accessing expertise that spans from research to product development to operations to attracting investment to successful product launch enhances our company’s ability to be the global leader in the development, production and distribution of bacteriophage products.”

Cytophage is a leading-edge, Canadian biotech company that uses advanced molecular genetic techniques and synthetic biology to create highly effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security.

For further information:                                       

Heather Medwick, President                                                

Phone:  431-388-8873

Email:  heather@cytophage.com